HDAC9 and myeloid sarcoma: Of note, HDAC inhibition can decrease the levels and activity of platelets in preclinical models [168], suggesting that gut dysbiosis associated with reduced butyrate levels may act to potentiate the role of platelets and coagulation factors in MS.